10x Genomics, Inc. (TXG) is a Healthcare company in the Health Information Services industry with a 59% Hold Score. Key strengths include Gross Margin (69.1%), Debt/Equity (0.11). Areas to watch: Net Margin (-6.8%), Return on Equity (-5.8%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.
This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.
See how our AI analyzes TXG fundamentals to generate buy/sell signals and Strong Buy Scores.
Our AI evaluates 10x Genomics, Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Hold rating:
Key developments and data points that may impact 10x Genomics, Inc.'s trajectory:
How 10x Genomics, Inc. stacks up against comparable Healthcare companies on key metrics:
Every investment carries risk. Here are the specific risk factors our analysis identified for 10x Genomics, Inc.:
Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.
A snapshot of 10x Genomics, Inc.'s financial health based on the most recent filings:
Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.
Based on our AI-powered fundamental analysis, TXG has a Strong Buy Score of 59%, earning a "Hold" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.
10x Genomics, Inc. shows mixed fundamentals with some strengths and areas to monitor. Positives include Gross Margin (69.1%). Watch for Net Margin (-6.8%).
Our AI analyzes 10x Genomics, Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 59% score:
Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.
Technical traders can view real-time demand and supply zones for TXG on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.
With TXG currently trading at $23.27, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.
Subscribe to demand zone alerts to receive real-time notifications when TXG reaches key technical levels.
10x Genomics, Inc. operates in the Healthcare sector, specifically in Health Information Services. Understanding earnings trends is crucial for forecasting TXG's trajectory.
Current revenue growth of 0.6% slightly beats the average company.
Visit our Earnings Calendar to track upcoming TXG earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.
Our AI projects TXG's trajectory based on current fundamentals and historical patterns. With a 59% Strong Buy Score, here's what the data suggests:
Mixed Outlook: 10x Genomics, Inc. shows moderate fundamental strength. Revenue growth at 0.6% is positive but warrants monitoring. The stock may trade sideways or experience modest gains depending on execution and market conditions.
For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.
Understanding valuation is critical for determining if TXG is fairly priced. Here's the current snapshot:
Our AI weighs these metrics against growth rates and margin quality to determine if TXG offers compelling risk-adjusted returns at current prices.
Here's why investors are bullish on 10x Genomics, Inc.:
While these positives exist, investors should weigh them against the risks outlined in the bear case below.
Every investment carries risk. Here are potential concerns for TXG investors:
The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.
TXG Summary: 10x Genomics, Inc. earns a 59% Hold Score based on AI analysis of fundamental data. Trading at $23.27 with a $2.97B market cap, the stock presents a balanced risk/reward profile for the coming year.
Bull Case: Gross Margin (69.1%), Debt/Equity (0.11)
Watch: Net Margin (-6.8%), Return on Equity (-5.8%)
For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free TXG PDF report.
Deepen your understanding of the concepts used in this TXG analysis:
Learn how to evaluate stocks using financial statements and key metrics.
Understanding P/E RatioWhat P/E ratio tells you about a stock's valuation and growth expectations.
Return on Equity (ROE)Why ROE matters for stock selection and how to interpret it.
Stock Valuation MethodsCompare DCF, P/E, and other approaches to value stocks like TXG.
What Are Demand Zones?Find key support and resistance levels for TXG and other stocks.
How to Read Earnings ReportsUnderstand earnings per share, revenue surprises, and guidance.
Latest SEC filings for TXG explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.